Tickers

1. Composite Trajectory Verdict

Given ARDT's hospital-operating model with significant lease obligations (Ventas Master Lease) and self-insured liability exposure, all three statements carry weight: the income statement reveals margin pressure from rising professional fees and liability costs, the cash flow statement shows operating cash generation outpacing earnings, and the balance sheet reflects stable leverage but growing self-insured reserves.

Composite Trajectory: Mixed

Revenue and operating cash flow are on an improving trend: annual revenue rose 6.0% to $6.324B in FY 2025 (10-K 2025-12-31, Consolidated Statements of Operations) and 2.6% to $3.224B in YTD 2026 (10-Q 2026-06-30, Consolidated Statements of Operations), while operating cash flow increased 49.4% to $470.5M in FY 2025 (10-K 2025-12-31, Consolidated Statements of Cash Flows) and 47.2% to $136.5M in YTD 2026 (10-Q 2026-06-30, Consolidated Statements of Cash Flows). Profitability is deteriorating: net income attributable to Ardent fell from $210.3M in FY 2024 to $135.8M in FY 2025 (10-K 2025-12-31, Consolidated Statements of Operations) and from $114.3M in YTD 2025 to $56.7M in YTD 2026 (10-Q 2026-06-30, Consolidated Statements of Operations). Professional fees rose from 18.4% to 18.9% of revenue annually and from 18.1% to 20.2% in Q2 (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A), and other operating expenses jumped from 8.2% to 10.3% annually driven by $51.3M of adverse professional liability developments (10-K 2025-12-31, MD&A). The balance sheet shows stable net leverage (0.8x) but lease-adjusted leverage ticked up to 2.6x (10-Q 2026-06-30, Liquidity) and self-insured liabilities grew to $284.6M (10-K 2025-12-31, Balance Sheet).

2. Red Flags

• Net income declining despite revenue growth: Net income attributable to Ardent dropped 35.4% YoY in FY 2025 ($210.3M → $135.8M) and 50.4% YoY in YTD 2026 ($114.3M → $56.7M) while revenue grew (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Consolidated Statements of Operations).
• Professional fees rising faster than revenue: Professional fees increased from 18.4% to 18.9% of revenue in FY 2025 and from 18.1% to 20.2% in Q2 2026 (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).
• Large recurring professional liability losses: $51.3M of adverse prior-period claim developments recorded in FY 2025, including $54.5M in Q3 2025 tied to a single provider (10-K 2025-12-31, MD&A and Note 11). Self-insured liabilities grew from $240.0M to $284.6M (10-K 2025-12-31, Balance Sheet).
• Medicaid supplemental payment volatility: Revenue from these programs swung from $530.3M (FY 2024) to $707.5M (FY 2025) (10-K 2025-12-31, MD&A), and Q2 2026 saw a $57.8M decrease due to delayed New Mexico renewal (10-Q 2026-06-30, MD&A).
• Accounting estimate change reduced revenue: $42.6M reduction in FY 2025 revenue from modified collectability estimation (10-K 2025-12-31, MD&A and Critical Accounting Policies).
• Widening gap between operating cash flow and net income: FY 2025 operating cash flow $470.5M vs net income $230.1M; YTD 2026 operating cash flow $136.5M vs net income $93.2M (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows).
• Lease-adjusted leverage increasing: Rose from 2.5x (FY 2025) to 2.6x (Q2 2026) (10-K 2025-12-31, Liquidity; 10-Q 2026-06-30, Liquidity).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment: Net income attributable to Ardent Health, Inc. has declined sharply across both annual and year-to-date comparisons. FY 2025 net income attributable to Ardent fell to $135.8M from $210.3M in FY 2024 (10-K 2025-12-31, Consolidated Statements of Operations). YTD 2026 net income attributable to Ardent fell to $56.7M from $114.3M in YTD 2025 (10-Q 2026-06-30, Consolidated Statements of Operations). Total revenue grew 6.0% annually and 2.6% YTD, but total operating expenses rose faster: 7.8% annually (95.5% vs 93.9% of revenue) and 5.4% YTD (96.3% vs 93.8% of revenue) (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Consolidated Statements of Operations). The primary drivers were professional fees (18.9% of revenue in FY 2025 vs 18.4% in FY 2024; 20.2% in Q2 2026 vs 18.1% in Q2 2025) and other operating expenses (10.3% in FY 2025 vs 8.2% in FY 2024; 10.5% in YTD 2026 vs 9.5% in YTD 2025), the latter inflated by $51.3M of professional liability losses in FY 2025 (10-K 2025-12-31, MD&A). Income before tax margin compressed from 6.1% to 4.5% annually and from 6.2% to 3.7% YTD (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Overall Assessment: Operating cash flow has grown strongly and consistently. FY 2025 net cash from operations reached $470.5M, up 49.4% from $315.0M in FY 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). YTD 2026 operating cash flow was $136.5M, up 47.2% from $92.7M in YTD 2025 (10-Q 2026-06-30, Consolidated Statements of Cash Flows). The FY 2025 increase was driven by favorable working capital changes, particularly increases in accounts payable from timing of payments and strategic cash management (10-K 2025-12-31, MD&A). The YTD 2026 increase reflected $102.9M of positive working capital changes, primarily from prepaid expenses/other current assets (timing of Medicaid supplemental funding) and accrued salaries (10-Q 2026-06-30, MD&A). Capital expenditures remained elevated at $211.9M in FY 2025 and $66.8M in YTD 2026 (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A). Free cash flow (operating cash flow less capex) was $258.6M in FY 2025 and $69.7M in YTD 2026. Cash and cash equivalents grew from $556.8M (FY 2024) to $709.6M (FY 2025) to $724.5M (Q2 2026) (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Stable

Overall Assessment: The balance sheet shows modest growth in assets and liabilities with stable leverage metrics. Total assets increased 6.7% from $4.956B (FY 2024) to $5.290B (FY 2025) and were essentially flat at $5.280B in Q2 2026 (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet). Total liabilities rose 5.0% from $3.434B to $3.605B in FY 2025, then declined slightly to $3.539B in Q2 2026 (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet). Long-term debt remained stable around $1.075B (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet). Net leverage held at 0.8x in both FY 2025 and Q2 2026; lease-adjusted net leverage edged up from 2.5x to 2.6x (10-K 2025-12-31, Liquidity; 10-Q 2026-06-30, Liquidity). Self-insured liabilities grew from $240.0M to $284.6M in FY 2025 and stood at $242.8M in Q2 2026 (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet). Equity attributable to Ardent rose from $1.131B to $1.288B in FY 2025 and to $1.351B in Q2 2026 (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet). No near-term debt maturities of concern; Term Loan B matures 2032, 5.75% Senior Notes 2029 (10-K 2025-12-31, Senior Secured Credit Facilities and 5.75% Senior Notes).

6. Data Gaps

• Quarterly trends for Q1 2026, Q3 2025, Q2 2025, Q1 2025 (only Q2 2026 and YTD 2026 provided in the 10-Q 2026-06-30 filing)
• Standalone Q3 and Q4 2025 income statement and cash flow detail (10-K provides only full-year 2025)
• Segment-level revenue and expense breakdowns (filings note a single reportable segment)
• Detailed working capital components for FY 2025 (only summary commentary provided)
• Interest coverage ratio and debt service coverage ratio calculations (not explicitly disclosed)
• Breakdown of "Other operating expenses" beyond the professional liability and provider assessment commentary